Japan Medical Group To Prevent Repeats Of Tainted Novartis Diovan Trials
This article was originally published in PharmAsia News
Executive Summary
The Japanese Association of Medical Sciences has called a meeting to discuss ways to improve the nation's process of clinical trials in the wake of revelations Novartis studies of its Diovan (valsartan) blood-pressure drug may have been tainted.